Dompé Biotec

Dompé is a leading Italian biopharmaceutical company that has evolved from a historic pharmacy into a global leader in biotechnology and rare disease research. The company is best known for developing Oxervate (cenegermin), the first-ever topical biologic treatment for neurotrophic keratitis, which utilizes recombinant human nerve growth factor (rhNGF). Dompé leverages its proprietary AI-powered platform, Exscalate, to accelerate drug discovery across ophthalmology, neurology, and metabolic diseases. With a state-of-the-art manufacturing and R&D hub in L'Aquila, Italy, and a significant presence in the United States and China, the company maintains a robust pipeline including late-stage candidates for atopic keratoconjunctivitis and type 1 diabetes. As a privately held, family-owned enterprise, Dompé is committed to high-impact scientific innovation and addressing significant unmet medical needs.